PharmaCyte Biotech, Inc.
Close on Oct 19, 2026
- Market cap
- $3.67M
- P/E (TTM)
- –
- Dividend yield
- –
About PharmaCyte Biotech
Biological Products, (No Diagnostic Substances), SIC 2836
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company that develops cellular therapies for the treatment of cancer. The company utilizes a proprietary cellulose-based live cell encapsulation platform called Cell-in-a-Box to produce treatments for various solid tumors. Its primary product candidate, CypCaps, consists of pinhead-sized porous capsules housing genetically modified human cells. These encapsulated cells are engineered to convert inactive cancer prodrugs into active chemotherapy agents directly at tumor sites, such as locally advanced, inoperable, non-metastatic pancreatic cancer. Because the company remains in the research and regulatory evaluation phase, its therapies are targeted toward oncology patients.
The company conducts its corporate administration and development oversight from its principal executive offices located in Las Vegas, Nevada. Its operational scope centers on preclinical research, regulatory evaluations involving the United States Food and Drug Administration, and collaboration with partner SG Austria Pte. Ltd., which holds technical know-how for the encapsulation technology.
Summary of the business section of PharmaCyte Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PharmaCyte Biotech, Inc.
- Headquarters
- Las Vegas, NV
- Address
- 3960 Howard Hughes Parkway, Suite 500 89169
- Phone
- (917) 595-2850
- Employees
- 2, Apr 30, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- April 30
- Auditor
- CBIZ CPAs P.C, Morristown, New Jersey
Stock & identifiers
- Ticker
- PMCB
- Exchange
- Nasdaq
- Shares outstanding
- 11M, Sep 11, 2026
- Public float
- $6.28M, Oct 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-1500 reverse, Aug 10, 2021; 1-for-1550 reverse, Jul 12, 2021
- SEC CIK
- 1157075
- CUSIP
- 71715X203
- ISIN
- US71715X2036
- EIN
- 62-1772151
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joshua Silverman | CEO and President, Director | 466,250 |
| Wayne Remell Walker | Director | 37,500 |
| Robert Weinstein | Director | 41,250 |
| Michael M. Abecassis | Director | 23,092 |
| Jonathan Schechter | Director | 192,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Kenneth L.Waggoner | $0 | $0 | $482.02K | $53 | – |
| FY2025 Mr.Joshua NSilverman | $520.26K | $594.69K | $482.02K | $53 | – |
| FY2024 Kenneth L.Waggoner | $0 | $0 | $636.12K | $91 | – |
| FY2024 Mr.Joshua NSilverman | $829.59K | $828.07K | $636.12K | $91 | – |
| FY2023 Kenneth L.Waggoner | $441.22K | $441.27K | $225.96K | $125 | – |
| FY2023 Mr.Joshua NSilverman | $197.92K | $197.92K | $225.96K | $125 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of April 30, 2026, we had two full-time employees and several consultants who devote substantial time to us.”
Corporate history
Events identified from SEC filings